vs
Side-by-side financial comparison of BELDEN INC. (BDC) and Hologic (HOLX). Click either name above to swap in a different company.
Hologic is the larger business by last-quarter revenue ($1.0B vs $696.4M, roughly 1.5× BELDEN INC.). Hologic runs the higher net margin — 17.1% vs 7.3%, a 9.8% gap on every dollar of revenue. On growth, BELDEN INC. posted the faster year-over-year revenue change (11.4% vs 2.5%). Hologic produced more free cash flow last quarter ($215.2M vs $-63.1M). Over the past eight quarters, BELDEN INC.'s revenue compounded faster (7.3% CAGR vs 1.5%).
Belden Inc. is an American, multinational, publicly traded company specializing in the design, manufacture, and distribution of end-to-end networking, security and connectivity products. The company serves the Industrial Automation Solutions, Smart Buildings and Broadband & 5G markets.
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
BDC vs HOLX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $696.4M | $1.0B |
| Net Profit | $51.0M | $179.1M |
| Gross Margin | 37.1% | 56.0% |
| Operating Margin | 11.2% | 22.6% |
| Net Margin | 7.3% | 17.1% |
| Revenue YoY | 11.4% | 2.5% |
| Net Profit YoY | -1.8% | -10.9% |
| EPS (diluted) | $1.30 | $0.79 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $696.4M | — | ||
| Q4 25 | $720.1M | $1.0B | ||
| Q3 25 | $698.2M | $1.0B | ||
| Q2 25 | $672.0M | $1.0B | ||
| Q1 25 | $624.9M | $1.0B | ||
| Q4 24 | $666.0M | $1.0B | ||
| Q3 24 | $654.9M | $988.0M | ||
| Q2 24 | $604.3M | $1.0B |
| Q1 26 | $51.0M | — | ||
| Q4 25 | $67.9M | $179.1M | ||
| Q3 25 | $56.7M | $187.2M | ||
| Q2 25 | $61.0M | $194.9M | ||
| Q1 25 | $51.9M | $-17.4M | ||
| Q4 24 | $58.4M | $201.0M | ||
| Q3 24 | $53.7M | $178.6M | ||
| Q2 24 | $49.0M | $194.5M |
| Q1 26 | 37.1% | — | ||
| Q4 25 | 36.6% | 56.0% | ||
| Q3 25 | 37.7% | 55.6% | ||
| Q2 25 | 38.5% | 56.3% | ||
| Q1 25 | 39.3% | 37.5% | ||
| Q4 24 | 37.5% | 56.8% | ||
| Q3 24 | 37.3% | 56.4% | ||
| Q2 24 | 37.5% | 55.4% |
| Q1 26 | 11.2% | — | ||
| Q4 25 | 12.2% | 22.6% | ||
| Q3 25 | 10.9% | 22.6% | ||
| Q2 25 | 11.8% | 24.9% | ||
| Q1 25 | 11.6% | -0.7% | ||
| Q4 24 | 10.4% | 22.5% | ||
| Q3 24 | 11.5% | 23.3% | ||
| Q2 24 | 11.4% | 24.1% |
| Q1 26 | 7.3% | — | ||
| Q4 25 | 9.4% | 17.1% | ||
| Q3 25 | 8.1% | 17.8% | ||
| Q2 25 | 9.1% | 19.0% | ||
| Q1 25 | 8.3% | -1.7% | ||
| Q4 24 | 8.8% | 19.7% | ||
| Q3 24 | 8.2% | 18.1% | ||
| Q2 24 | 8.1% | 19.2% |
| Q1 26 | $1.30 | — | ||
| Q4 25 | $1.70 | $0.79 | ||
| Q3 25 | $1.41 | $0.84 | ||
| Q2 25 | $1.53 | $0.86 | ||
| Q1 25 | $1.27 | $-0.08 | ||
| Q4 24 | $1.41 | $0.87 | ||
| Q3 24 | $1.30 | $0.75 | ||
| Q2 24 | $1.19 | $0.82 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $272.2M | $2.4B |
| Total DebtLower is stronger | $1.3B | $2.5B |
| Stockholders' EquityBook value | $1.3B | $5.2B |
| Total Assets | — | $9.2B |
| Debt / EquityLower = less leverage | 0.98× | 0.48× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $272.2M | — | ||
| Q4 25 | $389.9M | $2.4B | ||
| Q3 25 | $314.3M | $2.2B | ||
| Q2 25 | $301.5M | $1.9B | ||
| Q1 25 | $259.0M | $1.6B | ||
| Q4 24 | $370.3M | $2.0B | ||
| Q3 24 | $323.0M | $2.3B | ||
| Q2 24 | $564.8M | $2.4B |
| Q1 26 | $1.3B | — | ||
| Q4 25 | — | $2.5B | ||
| Q3 25 | — | $2.5B | ||
| Q2 25 | — | $2.5B | ||
| Q1 25 | — | $2.5B | ||
| Q4 24 | — | $2.5B | ||
| Q3 24 | — | $2.5B | ||
| Q2 24 | — | $2.5B |
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.3B | $5.2B | ||
| Q3 25 | $1.2B | $5.0B | ||
| Q2 25 | $1.2B | $4.8B | ||
| Q1 25 | $1.2B | $4.6B | ||
| Q4 24 | $1.3B | $4.8B | ||
| Q3 24 | $1.2B | $5.1B | ||
| Q2 24 | $1.2B | $5.0B |
| Q1 26 | — | — | ||
| Q4 25 | $3.5B | $9.2B | ||
| Q3 25 | $3.4B | $9.0B | ||
| Q2 25 | $3.4B | $8.8B | ||
| Q1 25 | $3.3B | $8.5B | ||
| Q4 24 | $3.3B | $8.7B | ||
| Q3 24 | $3.3B | $9.2B | ||
| Q2 24 | $3.5B | $8.9B |
| Q1 26 | 0.98× | — | ||
| Q4 25 | — | 0.48× | ||
| Q3 25 | — | 0.50× | ||
| Q2 25 | — | 0.52× | ||
| Q1 25 | — | 0.55× | ||
| Q4 24 | — | 0.53× | ||
| Q3 24 | — | 0.49× | ||
| Q2 24 | — | 0.51× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $229.9M |
| Free Cash FlowOCF − Capex | $-63.1M | $215.2M |
| FCF MarginFCF / Revenue | -9.1% | 20.5% |
| Capex IntensityCapex / Revenue | 6.4% | 1.4% |
| Cash ConversionOCF / Net Profit | — | 1.28× |
| TTM Free Cash FlowTrailing 4 quarters | $180.4M | $1.0B |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $160.4M | $229.9M | ||
| Q3 25 | $105.0M | $355.1M | ||
| Q2 25 | $82.0M | $343.3M | ||
| Q1 25 | $7.4M | $169.4M | ||
| Q4 24 | $174.7M | $189.3M | ||
| Q3 24 | $91.7M | $367.0M | ||
| Q2 24 | $83.0M | $405.8M |
| Q1 26 | $-63.1M | — | ||
| Q4 25 | $121.3M | $215.2M | ||
| Q3 25 | $65.3M | $341.4M | ||
| Q2 25 | $56.9M | $330.5M | ||
| Q1 25 | $-24.8M | $153.9M | ||
| Q4 24 | $116.4M | $172.5M | ||
| Q3 24 | $67.2M | $350.6M | ||
| Q2 24 | $61.0M | $385.3M |
| Q1 26 | -9.1% | — | ||
| Q4 25 | 16.8% | 20.5% | ||
| Q3 25 | 9.4% | 32.5% | ||
| Q2 25 | 8.5% | 32.3% | ||
| Q1 25 | -4.0% | 15.3% | ||
| Q4 24 | 17.5% | 16.9% | ||
| Q3 24 | 10.3% | 35.5% | ||
| Q2 24 | 10.1% | 38.1% |
| Q1 26 | 6.4% | — | ||
| Q4 25 | 5.4% | 1.4% | ||
| Q3 25 | 5.7% | 1.3% | ||
| Q2 25 | 3.7% | 1.3% | ||
| Q1 25 | 5.2% | 1.5% | ||
| Q4 24 | 8.8% | 1.6% | ||
| Q3 24 | 3.7% | 1.7% | ||
| Q2 24 | 3.6% | 2.0% |
| Q1 26 | — | — | ||
| Q4 25 | 2.36× | 1.28× | ||
| Q3 25 | 1.85× | 1.90× | ||
| Q2 25 | 1.34× | 1.76× | ||
| Q1 25 | 0.14× | — | ||
| Q4 24 | 2.99× | 0.94× | ||
| Q3 24 | 1.71× | 2.05× | ||
| Q2 24 | 1.69× | 2.09× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BDC
Segment breakdown not available.
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
